UBS/CALL/MODERNA/160.001/0.1/20.12.24 | Real-time Bid/Ask 08:22:52 2024-05-24 EDT | ||
| 2.81 CHF / 2.84 CHF | +5.02% |
|
| Current month | +348.33% | ||
| 1 month | +427.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 2.69 | +12.08% |
| 24-05-22 | 2.4 | +72.66% |
| 24-05-21 | 1.39 | +33.65% |
| 24-05-16 | 1.04 | +19.54% |
| 24-05-15 | 0.87 | -9.37% |
Delayed Quote Swiss Exchange
Last update May 23, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| QMRNOU | |
| ISIN | CH1312549806 |
| Date issued | 2024-01-08 |
| Strike | 160 $ |
| Maturity | 2024-12-20 (210 Days) |
| Parity | 10 : 1 |
| Emission price | 0.95 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.69 CHF |
|---|---|
| Lowest since issue | 0.25 CHF |
| Spread | 0.03 CHF |
| Spread % | 1.06% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
164
USD
Average target price
138.5
USD
Spread / Average Target
-15.55%
- Stock Market
- Warrants
- QMRNOU Warrant
